# Turenne Capital

> Turenne Capital is a VC fund in Paris backing Software and Biotechnology. See 56 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Paris, France
- Total investments: 56
- Last investment: Feb 2026
- Lead investor: 25%
- Fund size: $35M
- Last fund: Jun 2020
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/turenne-capital/
- X (Twitter): https://twitter.com/turenne_capital
- Website: http://www.turennecapital.com

Turenne Capital is an independant private equity management company, with 4 offices in France : - Paris - Lyon - Marseilles - Lille (joint-venture). Since 1999, Turenne Capital has been taking significant minority or majority equity stakes alongside entrepreneurs who operate SMEs with revenues ranging from €5 million to € 100 million. Itinvests between €1 million and €10 million per transaction. Turenne Capital manages/advises more than € 500 million. 32 people, among which 21 investors work in the Group. ------------------------------------------------------------------------------ Turenne Capital est une Société de gestion indépendante spécialisée en capital investissement. Turenne Capital accompagne depuis 1999 des entrepreneurs dans leur développement et la transmission de leur société et est implantée à : - Paris - Lyon - Marseille - Lille (filiale) Les tickets d'investissement vont de '1 à 10 millions d'euros en minoritaire et majoritaire dans des PME de 5 à 100 M€ de Chiffre d'affaires. Le Groupe Turenne Capital compte 32 professionnels dont 21 investisseurs, et gère/conseille plus de 500 M€ confiés par des institutionnels et des particuliers.

## Contacts

5 contacts available for Turenne Capital. Shizune tracks 20 team members at Turenne Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/turenne-capital?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $2.8M–$33M |
| Series B | $6.6M–$30M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Software | 13 | 23% |
| Biotechnology | 8 | 14% |
| Health Care | 7 | 13% |
| Medical | 6 | 11% |
| Information Technology | 5 | 9% |

82 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Funding Round | 16 | 29% |
| Series A | 13 | 23% |
| Series B | 8 | 14% |
| Private Equity | 8 | 14% |
| Venture - Series Unknown | 5 | 9% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| France | 47 | 84% |
| Poland | 1 | 2% |
| Germany | 1 | 2% |
| United States | 1 | 2% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Alice Maurel | Marketing Assistant | 0 | https://shizune.co/investors/profile/alice-maurel |
| Angélica Marlet | Assistant | 0 | https://shizune.co/investors/profile/anglica-marlet |
| Aurélie Viaux | Account Manager | 0 | https://shizune.co/investors/profile/aurlie-viaux |
| Béatrice Vernet | Secretary General | 0 | https://shizune.co/investors/profile/batrice-vernet |
| Benoît Pastour | Deputy CEO | 0 | https://shizune.co/investors/profile/benot-pastour |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Kainova Therapeutics | Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs), one of the best classes of drug targets. Domain Therapeutics is using its innovative and proprietary technology platform DTect-Allâ„¢ to identifyorthosteric and allosteric ligands of GPCRs, including the so called Silent Allosteric Modulators (SAMs) that represent a unique source of compounds that cannot be discovered by standard technologies. DTect-Allâ„¢ is able to address difficult GPCRs such as orphan and peptidic GPCRs. | $23.5M | Series B | Feb 09, 2026 |  |
| Germitec SAS | Germitec is a healthcare company that designs, Commercialize UV-C disinfection systems for hospital hygiene system. | $30.1M | Series B | Feb 12, 2025 |  |
| Coave Therapeutics | Coave Therapeutics is active in the field of gene therapies in rare ocular and CNS (Central Nervous System) diseases. | $32.9M | Series A | Jan 09, 2025 |  |
| Sydev | Sydev is a publisher of management software and tariff databases for technical building trades in the construction industry. | $11.1M | Venture - Series Unknown | Sep 27, 2024 |  |
| Antabio | Antabio is a private biopharmaceutical company developing novel antibacterial resistance-breakers to treat drug-resistant infections in areas of highest unmet medical need. It develops stand-alone inhibitors of bacterial metalloenzymes that can be combined with various antibiotics to restore their activity against the most critical pathogens. Thecompany's novel inhibitor of bacterial Metallo ß-lactamases (“MBLs”) which will be combined with a carbapenem to fill an important gap in the treatment of drug-resistant infections. They develop a novel, safe and efficacious inhibitor of bacterial Metallo ß-lactamases to be combined with a carbapenem for the treatment of drug-resistant nosocomial infections.Antabio received a Wellcome Trust Seeding Drug Discovery Award. The company was founded in 2009 and is headquartered in Labege, France. | $27M | Series B | Dec 12, 2023 |  |
| AlgoTherapeutix | AlgoTherapeutix is the operator of a biotechnology company designed to develop topical treatments for complex pain. | $21.5M | Series B | Mar 14, 2023 |  |
| Amolyt Pharma | Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders. Its programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism, and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism. | $138.6M | Series C | Jan 06, 2023 |  |
| Tradim | Tradim delivers commission, development and maintenance activities for the waste management hardware and integrated software. | $19.5M | Venture - Series Unknown | Oct 13, 2022 |  |
| Kainova Therapeutics | Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs), one of the best classes of drug targets. Domain Therapeutics is using its innovative and proprietary technology platform DTect-Allâ„¢ to identifyorthosteric and allosteric ligands of GPCRs, including the so called Silent Allosteric Modulators (SAMs) that represent a unique source of compounds that cannot be discovered by standard technologies. DTect-Allâ„¢ is able to address difficult GPCRs such as orphan and peptidic GPCRs. | $41.1M | Series A | May 10, 2022 |  |
| PathoQuest | PathoQuest SAS, a spin off of Institut Pasteur, is a biotechnology company offering a game changing metagenomics approach to improving the breadth of pathogen detection. The company’s proprietary next generation sequencing (NGS) based testing approach delivers actionable reports to clinicians, biologists and biopharmaceutical quality assurancemanagers/production managers.PathoQuest’s proprietary sample preparation, and its comprehensive database of pathogens genomic information, enables clinicians and biopharma companies to overcome the current limitation of infectious agent detection.PathoQuest’s Viral Safety testing service, directed towards biopharmaceutical companies, is the company’s first commercial application of its testing approach and has quickly established a revenue stream for the company from several major biopharma companies. | $15.9M | Series B | Nov 09, 2021 |  |

10 of 56 investments shown.

## Co-investors
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund, 7 deals together
- [Kurma Partners](https://shizune.co/investors/profile/kurma-life-science-partners) — VC Fund, 5 deals together
- [Paca Investissement](https://shizune.co/investors/profile/paca-investissement) — VC Fund, 5 deals together
- [Eurazeo](https://shizune.co/investors/profile/eurazeo-com) — VC Fund, 4 deals together
- [Omnes Capital](https://shizune.co/investors/profile/omnes-capital) — VC Fund, 4 deals together
- [Panacea Venture](https://shizune.co/investors/profile/panacea-venture) — VC Fund, 3 deals together

## Similar investors

### Similar industry
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [Aster](https://shizune.co/investors/profile/aster-capital) — VC Fund
- [Eleven Ventures](https://shizune.co/investors/profile/eleven) — VC Fund

### Similar stage
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund

### Similar country
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [Kima Ventures](https://shizune.co/investors/profile/kima-ventures) — VC Fund
- [Motier Ventures](https://shizune.co/investors/profile/motier-ventures) — VC Fund

## Featured in investor lists
- [Enterprise VC Funds in France](https://shizune.co/investors/enterprise-vc-funds-france)
- [Software VC Funds in France](https://shizune.co/investors/software-vc-funds-france)
- [Marketplace VC Funds in France](https://shizune.co/investors/marketplace-vc-funds-france)
- [Hardware Investors in France](https://shizune.co/investors/hardware-investors-france)
- [Hardware VC Funds in France](https://shizune.co/investors/hardware-vc-funds-france)
- [Consumer VC Funds in France](https://shizune.co/investors/consumer-vc-funds-france)

## FAQ

### What does Turenne Capital invest in?

Turenne Capital invests primarily in Software, Biotechnology and Health Care startups, most often at Funding Round and Series A stage. Most of the 56 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Turenne Capital's check size?

Turenne Capital typically joins rounds of $2.8M–$33M at Series A and $6.6M–$30M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Turenne Capital participates in.

### How do I contact Turenne Capital?

Public channels for Turenne Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Turenne Capital?

The team at Turenne Capital includes Alice Maurel (Marketing Assistant), Angélica Marlet (Assistant) and Aurélie Viaux (Account Manager), among 20 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co